Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria-Reference-Cited by-同舟云学术

Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria

Published:2016-05 Issue:3 Volume:4 Page:529-530
ISSN:2213-2198
Container-title:The Journal of Allergy and Clinical Immunology: In Practice
language:en
Short-container-title:The Journal of Allergy and Clinical Immunology: In Practice

Author:

Palacios Thamiris,Stillman Leland^ORCID,Borish Larry,Lawrence Monica

Publisher

Elsevier BV

Subject

Immunology and Allergy

Reference9 articles.

1. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy;Kaplan;J Allergy Clin Immunol,2013

2. Basophil phenotypes in chronic idiopathic urticaria in relation to disease activity and autoantibodies;Eckman;J Invest Dermatol,2008

3. The autologous serum skin test in a cohort of chronic idiopathic urticaria patients compared to respiratory allergy patients and healthy individuals;Guttman-Yassky;J Eur Acad Dermatol Venereol,2007

4. Independent evaluation of a commercial test for “autoimmune” urticaria in normal and chronic urticaria subjects;Eckman;J Invest Dermatol,2009

5. Chronic urticaria sera increase basophil CD203c expression;Yasnowsky;J Allergy Clin Immunol,2006

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Autoimmune Mast Cell Activation Test as a Diagnostic Tool in Chronic Spontaneous Urticaria;International Journal of Molecular Sciences;2024-08-27

2. Biomarkers for Short-Term Omalizumab Response in Chronic Spontaneous Urticaria;Annals of Dermatology;2024

3. BTK signaling—a crucial link in the pathophysiology of chronic spontaneous urticaria;Journal of Allergy and Clinical Immunology;2023-12

4. Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status;Dermatology and Therapy;2023-09-30

5. Elevated baseline soluble FcεRI may be linked to early response to omalizumab treatment in chronic spontaneous urticaria;Journal of the European Academy of Dermatology and Venereology;2023-09-09